AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Digital Engagement for Lifelong Health

RecruitingNAAges 18 Years - 65 YearsAllIstituto per la Ricerca e l'Innovazione Biomedica
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The DELPHI project (Digital Engagement for Lifelong Prevention and Health Improvement) aims to develop, implement, and validate an advanced digital platform for promoting well-being and personalized prevention of chronic non-communicable diseases in healthy adults. By integrating wearable sensors, artificial intelligence, federated learning, and the Human Digital Twin (HDT) paradigm, the DELPHI platform is designed to collect, analyze, and interpret multidimensional data in order to deliver dynamic and personalized recommendations for healthy lifestyles. The study adopts a multicenter, randomized controlled pilot design, with a maximum duration of 12 months per participant. A total of 200 healthy adults aged 18-65 will be recruited in Southern Italy (Sicily, Campania, and Basilicata) and randomly assigned to either: (1) an experimental group using the full DELPHI platform, including per

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Apparent good general health status, confirmed by medical history and initial self-assessment. * Ability to understand the study information and provide informed consent. * Availability and motivation to participate for the entire duration of the study (12 months). * Access to a smartphone compatible with the DELPHI application. * Willingness to wear the wearable devices for continuous monitoring of physiological parameters. * Basic familiarity with mobile applications or willingness to receive training on their use. * Signed informed consent. Exclusion Criteria: * Presence of severe chronic diseases in active phase (e.g., oncological, cardiovascular, or neurological diseases). * Acute or unstable conditions that could compromise participation in the protocol. * Current pregnancy. * Diagnosed major cognitive or psychiatric disorders that hinder understanding of or adherence to the protocol. * Current use of medications that significantly affect the parameters being monitored (e.g., psychotropic drugs, beta-blockers). * Simultaneous participation in other clinical studies. * Logistical difficulties that prevent frequent interaction with the platform (e.g., lack of connection, unwillingness to attend periodic follow-ups).
๐Ÿ’Š

What it tests

  • DELPHI Personalized Digital Prevention Platform
  • Passive Digital Monitoring Control
๐Ÿ“

Where

1 site
Institute for Biomedical Research and Innovation (IRIB)-National Reasearch Council (CNR)
Messina, Italy
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy